ANNEX V
TOXICOLOGICAL PROPERTIES
Section 1. No standard information or testing
1.1.
No standard information or testing is required for a relevant chemical species where either of the following conditions are fulfilled:
(a)
a parametric value for the relevant chemical species is set under Annex I to Directive (EU) 2020/2184;
(b)
a MTC tap value for the relevant chemical species in the applicable material type is set in the corresponding Annex to Implementing Decision (EU) 2024/367 following a decision by the Commission on an application for a starting substance, composition or constituent that has been submitted to ECHA under Article 4 of Delegated Regulation (EU) 2024/369 and the applicant submits at least any new or updated information available as from the date of the Commission’s decision;
(c)
the relevant chemical species is classified in Regulation (EC) No 1272/2008 of the European Parliament and of the Council ( 1 ) as one of the following:
(i)
Category 1A or 1B for carcinogenicity, mutagenicity or reproductive toxicity or Category 1 for endocrine disruption for human health;
(ii)
persistent bioaccumulative and toxic;
(iii)
very persistent and very bioaccumulative;
(iv)
persistent mobile and toxic;
(v)
very persistent and very mobile;
(d)
the relevant chemical species is identified as a substance of very high concern in the Candidate List established under Article 59 of Regulation (EC) No 1907/2006, except those identified on the basis of Article 57(f) of Regulation (EC) No 1907/2006 only for the environment;
(e)
the relevant chemical species is authorised as an active substance under Regulation (EU) No 528/2012 on the basis of an opinion of the Committee of the Risk Assessment of ECHA setting a defined safety threshold for the oral route and used as such in materials in contact with water under Product-type 6.
1.2.
No standard information or testing is required for a relevant chemical species, to the extent that a specific migration limit is set under Commission Regulation (EU) No 10/2011 for less than 15 years from the date of submission of the application under Article 3 of Delegated Regulation (EU) 2024/369.
Section 2. Standard information or testing required
Part 1. General and specific rules
1.1.
Testing under this Section shall be carried out in compliance with the principles of good laboratory practice provided for in Directive 2004/10/EC or other international standards recognised as being equivalent by the Commission or ECHA and with the provisions of Directive 2010/63/EU of the European Parliament and of the Council ( 2 ) , if applicable.
1.2.
Any applicant shall ensure that testing on vertebrate animals is carried out only when no alternative methods, identified under this Section, is available. If testing on vertebrate animals is unavoidable, such testing shall be designed, where appropriate, by taking into account the possibility to explore several parameters within the framework of one study (e.g. kinetic data generation, micronucleus formation, neurotoxicity, immunotoxicity) or to combine two studies (e.g. long-term toxicity study and carcinogenicity study) to the extent permitted by the corresponding test method.
1.3.
Testing under this Section shall be carried out in compliance with the appropriate test guideline determined and specified by ECHA and published on its website, taking into account in particular the requirements set out in Section 1.6.
1.4.
A stepwise approach for toxicological testing shall be applied based on the C tap of a relevant chemical species in water intended for human consumption. For the lowest migration concentration band, the standard information is set out in Table 1, and every time a new migration band is reached, the standard information set out in the corresponding Tables 2 and 3 shall be added.
Column 1 of Tables 1, 2 and 3 establishes the standard information for relevant chemical species.
Column 2 of Tables 1, 2 and 3 lists specific rules according to which the standard information and testing may be omitted.
Standard information and testing may be adapted according to the general rule set out in Part 2.
1.5.
Any other relevant toxicological information that is available shall be identified and considered.
1.6.
Where a test method offers flexibility in the determination or choice of the study design, including by not prohibiting certain study specifications, for example in relation to the choice of dose levels, the chosen study design shall ensure that the data generated are adequate for hazard identification and risk assessment. To this end, testing shall be performed at appropriately high dose levels. If dose (concentration) selection is limited by the physico-chemical properties or biological effects of the test substance, the applicant shall provide a scientifically robust justification.
Table 1
Standard information and testing – C tap below 2,5 μg/l
Column 1
Standard information and testing
Column 2
Specific rules for adaptation of the standard information and testing
6.1.
Genotoxicity/Mutagenicity:
6.1.1.
In vitro genetic toxicity
6.1.1.1.
In vitro gene mutation study in bacteria
The in vitro gene mutation study in bacteria does not need to be conducted if this test is not applicable for the relevant chemical species. In this case, the applicant shall provide a justification and perform an in vitro study referred to in point 6.1.1.3.
The study does not need to be conducted for nanoforms where it is not appropriate. In this case, other studies involving one or more in vitro mutagenicity studies in mammalian cells shall be provided.
6.1.1.2.
In vitro mammalian chromosomal aberration study or in vitro mammalian micronucleus study
The study does not need to be carried out if an adequate data from an in vivo cytogenicity test is available.
6.1.1.3.
In vitro gene mutation test in mammalian cells
The study shall be carried out in the following cases:
(a)
there are negative results in both in vitro studies referred to in points 6.1.1.1. and 6.1.1.2.;
(b)
the in vitro study referred to in point 6.1.1.1. is inapplicable to the relevant chemical species.
The study does not need to be carried out if there are adequate data from a reliable in vivo mammalian gene mutation test.
6.1.2.
In vivo genetic toxicity
6.1.2.1.
An appropriate in vivo mammalian somatic cell genotoxicity study
The study shall be carried out if there is a positive result in any of the in vitro genotoxicity study referred to in point 6.1.1. which gives rise to a concern.
The study shall address the chromosomal aberration concern or the gene mutation concern or both, as appropriate.
6.1.2.2.
An appropriate in vivo mammalian germ cell genotoxicity study
The study shall be carried out if there is a positive result in an available in vivo mammalian somatic cell genotoxicity study, which gives rise to concern.
The study shall address the chromosomal aberration concern or the gene mutation concern or both, as appropriate.
The study does not need to be conducted if there is clear evidence that neither the relevant chemical species nor its metabolites reach the germ cells.
6.2.
Appropriate toxicokinetic and metabolism studies in mammals, appropriate repeated dose toxicity study, appropriate reproductive toxicity study, appropriate carcinogenicity study or appropriate additional studies referred to in Tables 2 and 3
The study shall be carried out if there is any of the information available, raises a concern for at least one of the following hazard classes defined in Annex I to Regulation (EC) No 1272/2008: Specific Target Organ Toxicity – Repeat Exposure (STOT RE), Carcinogenicity, Mutagenicity or Reprotoxicity (CMR) or endocrine disruption for human health.
The study shall address each of the concerns identified.
Table 2
Standard information and testing – C tap equal to or above 2,5 μg/L and below 250 μg/L
Column 1
Standard information and testing
Column 2
Specific rules for adaptation of the standard information and testing
7.1.
Toxicokinetics and metabolism studies in mammals:
7.1.1.
Data to demonstrate the absence of potential for accumulation in human
7.2.
Repeated dose toxicity:
7.2.1.
Sub-chronic repeated dose toxicity study (90-days) in one animal species (rodents), male and female, via oral route of administration
The study does not need to be conducted where any of the following conditions are fulfilled:
(a)
a reliable short-term toxicity study (28 days) or a repeated dose toxicity study with the reproduction/developmental toxicity screening test is available showing severe toxicity effects according to the criteria for classifying the relevant chemical species as STOT RE (Regulation (EC) No 1272/2008), for which the observed No Observed Adverse Effect Level (NOAEL)-28 days, with the application of an appropriate assessment factor allows the extrapolation towards the NOAEL-90 days for the same route of exposure;
(b)
a reliable chronic toxicity study is available, in which an appropriate animal species and route of administration were used;
(c)
the relevant chemical species is unreactive, insoluble, not bioaccumulative and there is no evidence of absorption and no evidence of toxicity in a 28-day ‘limit test’.
7.3.
Reproductive toxicity:
7.3.1.
Reproduction/Developmental toxicity screening study
The study does not need to be conducted where any of the following conditions are fulfilled:
(a)
a reliable extended one-generation reproductive toxicity study is available, in which an appropriate animal species and route of administration were used;
(b)
the relevant chemical species is of low toxicological activity (no evidence of toxicity seen in any of the tests available provided that the dataset is sufficiently comprehensive and informative), it can be proven from toxicokinetic data that no systemic absorption occurs via the oral route of exposure, e.g., plasma/blood concentrations below detection limit using a sensitive method and the relevant chemical species and its metabolites are absent in urine or bile.
7.4.
Appropriate toxicokinetic and metabolism studies, appropriate repeated dose toxicity study, appropriate reproductive toxicity study, appropriate carcinogenicity study or appropriate additional studies referred to under Table 3
The study shall be carried out if any information available raises a concern for at least one of the following hazard classes defined in Annex I to Regulation (EC) No 1272/2008: STOT RE or CMR or endocrine disruption for human health.
The study shall address each of the concerns identified.
Table 3
Standard information and testing – C tap equal or above 250 μg/L
Column 1
Standard information and testing
Column 2
Specific rules for adaptation of the standard information and testing
8.1.
Toxicokinetics and metabolism studies in mammals:
8.1.1.
Study on absorption, distribution, metabolism and excretion
8.1.2.
Considerations on the potential need for additional toxicokinetic information
Additional information might be needed based on the outcome of the toxicokinetic and metabolism study conducted in rats or based on the evaluation of the toxicological and physicochemical profile of the relevant chemical species.
8.2.
Repeated dose toxicity:
8.2.1.
Long-term repeated dose toxicity (≥ 12 months), oral route of administration
This study does not need to be conducted if the combined chronic toxicity/carcinogenicity study referred to in point 8.4.1. is provided.
8.3.
Reproductive toxicity:
The studies do not need to be conducted where the relevant chemical species is of low toxicological activity (no evidence of toxicity seen in any of the tests available, in which a sufficiently comprehensive and informative dataset has been used), it can be proven from toxicokinetic data that no systemic absorption occurs via the oral route of exposure, e.g., plasma/blood concentrations below detection limit using a sensitive method and the relevant chemical species and its metabolites are absent in urine or bile.
8.3.1.
Extended one-generation reproductive toxicity study, oral route of administration
An Extended One-Generation Reproductive Toxicity Study with the extension of cohort 1B to include the F2 generation where any of the following conditions are met:
(a)
the relevant chemical species displays genotoxic effects in somatic cell mutagenicity tests in vivo which could lead to its classification as mutagen category 2;
(b)
there are indications that the internal dose for the relevant chemical species and/or any of its metabolites will reach a steady state in the test animals only after an extended exposure;
(c)
there are indications of one or more relevant modes of action related to endocrine disruption from available in vivo studies or non-animal approaches.
An Extended One-Generation Reproductive Toxicity Study including cohorts 2A/2B (developmental neurotoxicity) and/or cohort 3 (developmental immunotoxicity) shall be included in case of particular concerns on (developmental) neurotoxicity or (developmental) immunotoxicity justified by any of the following:
(a)
existing information on the relevant chemical species itself derived from relevant available in vivo or non-animal approaches (e.g., abnormalities of the central nervous system (CNS), evidence of adverse effects on the nervous or immune system in studies on adult animals or animals exposed prenatally);
(b)
specific mechanisms/modes of action of the relevant chemical species with an association to (developmental) neurotoxicity and/or (developmental) immunotoxicity (e.g., cholinesterase inhibition or relevant changes in thyroidal hormone levels associated to adverse effects);
(c)
existing information on effects caused by substances analogous to the relevant chemical species being studied, suggesting such effects or mechanisms/modes of action.
Two-generation reproductive toxicity studies that were initiated before 13 May 2015 shall be considered appropriate to address this standard information requirement.
8.3.2.
Prenatal developmental toxicity study, in rat, unless another animal species is justified to be more appropriate, oral route of administration
8.3.3.
Further pre-natal developmental toxicity study, in a second animal species, oral route of administration or mechanistic study
A decision on the need to perform additional studies on a second animal species or mechanistic studies shall be based on the outcome of the first test (point 8.3.2.) and all other relevant available data (in particular rodent reproductive toxicity studies).
8.4.
Carcinogenicity:
See 8.4.1 for new study requirements
The study does not need to be provided where all of the following conditions are fulfilled:
(a)
no genotoxic potential is identified in genotoxicity tests; and
(b)
the sub-chronic and long-term (≥ 12 months) toxicity studies show no evidence of toxicity at the limit dose level.
8.4.1
Combined Chronic Toxicity/Carcinogenicity study oral route of administration
The study does not need to be conducted if adequate data from a reliable carcinogenicity study, oral route of administration is available: in such circumstances the long term repeated dose toxicity study referred to in point 8.2.1. must be provided.
8.5.
Additional toxicity properties:
If there is an indication for one or more mechanisms/modes of action of the relevant chemical species with an association to (developmental) neurotoxicity and/or endocrine disruption and/or (developmental) immunotoxicity, corresponding additional data shall be generated in accordance with this point, unless already fully covered by the information under point 8.3.1.
8.5.1.
Appropriate neurotoxicity information or study, including developmental neurotoxicity, in rat, unless another animal species is justified to be more appropriate (e.g. adult hen for delayed neurotoxicity study), oral route of exposure
If anticholinesterase activity is detected, a test for response to reactivating agents shall be generated.
8.5.2.
Appropriate information or study on endocrine disruption, oral route of exposure if relevant
This standard information or study shall be generated if there is any evidence from in vitro studies or from repeated dose or reproduction toxicity studies, that the relevant chemical species may have endocrine disrupting properties for human health, in order to elucidate the mode/mechanism of action and provide sufficient evidence for relevant adverse effects.
8.5.3.
Appropriate immunotoxicity information or study, including developmental immunotoxicity
This standard information or study shall be generated if there is any evidence, from skin sensitisation, repeated dose or reproductive toxicity studies, that the relevant chemical species may have immunotoxic properties, in order to elucidate the mode/mechanism of action and provide sufficient evidence for relevant adverse effects.
8.5.4.
Appropriate mechanistic data or studies
This standard information or testing shall be generated if necessary to clarify any effects reported in toxicity studies.
Part 2. General rules for adaptation of Column 1 of Tables 1, 2 and 3
2.1.
The general rules for adaptation set under Sections 1 and 2 of Annex XI to Regulation (EC) No 1907/2006 shall apply mutatis mutandis with the exception set out in Section 2.2.
2.2.
The general rules for adaptation under Sections 1.3 (Qualitative or Quantitative structure-activity relationship ((Q)SAR)) and 1.5 (Grouping of substances and read-across approach) of Annex XI to Regulation (EC) No 1907/2006 shall apply to the standard information and testing referred to in Table 1, point 6.1.1., only in the case of a substance constituent or a non-intentionally added species for which experimental testing is not technically possible (e.g., it cannot be isolated and tested as such).
( 1 ) Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 ( OJ L 353, 31.12.2008, p. 1 ).
( 2 ) Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010. on the protection of animals used for scientific purposes ( OJ L 276, 20.10.2010, p. 33 ).